-
1
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
-
(2005)
N Engl J Med
, vol.352
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
van den Bent, M.J.3
-
2
-
-
65349121788
-
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
-
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459-466.
-
(2009)
Lancet Oncol
, vol.10
, pp. 459-466
-
-
Stupp, R.1
Hegi, M.E.2
Mason, W.P.3
-
3
-
-
77949891455
-
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma
-
Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28:1168-1174.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1168-1174
-
-
Wick, W.1
Puduvalli, V.K.2
Chamberlain, M.C.3
-
4
-
-
0032767387
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
-
Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17:2572-2578.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2572-2578
-
-
Wong, E.T.1
Hess, K.R.2
Gleason, M.J.3
-
5
-
-
0033897173
-
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
-
Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
-
(2000)
Br J Cancer
, vol.83
, pp. 588-593
-
-
Yung, W.K.1
Albright, R.E.2
Olson, J.3
-
6
-
-
0025141337
-
What is the evidence that tumors are angiogenesis dependent?
-
Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute. 1990;82:4-6.
-
(1990)
Journal of the National Cancer Institute
, vol.82
, pp. 4-6
-
-
Folkman, J.1
-
7
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clil Oncol. 2005;23:1011-1027.
-
(2005)
J Clil Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
8
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
9
-
-
0030576517
-
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
-
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
-
(1996)
Cell
, vol.86
, pp. 353-364
-
-
Hanahan, D.1
Folkman, J.2
-
10
-
-
34547122001
-
The 2007 WHO classification of tumours of the central nervous system
-
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;1:97-109.
-
(2007)
Acta Neuropathol
, vol.1
, pp. 97-109
-
-
Louis, D.N.1
Ohgaki, H.2
Wiestler, O.D.3
-
11
-
-
0036842215
-
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
-
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-4380.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4368-4380
-
-
Dvorak, H.F.1
-
13
-
-
84878969497
-
-
European Medicines Agency: Avastin (bevacizumab) product page
-
European Medicines Agency: Avastin (bevacizumab) product page. http://www.ema.europa.eu/docsenGB/documentlibrary/EPAR-Product.
-
-
-
-
14
-
-
33947304452
-
The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development
-
Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007;1:84-96.
-
(2007)
Curr Opin Drug Discov Devel
, vol.1
, pp. 84-96
-
-
Mould, D.R.1
Sweeney, K.R.2
-
15
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
16
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
17
-
-
37349080670
-
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial
-
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-2111.
-
(2007)
Lancet
, vol.370
, pp. 2103-2111
-
-
Escudier, B.1
Pluzanska, A.2
Koralewski, P.3
-
18
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357: 2666-2676.
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
19
-
-
84855466019
-
A phase 3 trial of bevacizumab in ovarian cancer
-
Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
-
(2011)
N Engl J Med
, vol.365
, pp. 2484-2496
-
-
Perren, T.J.1
Swart, A.M.2
Pfisterer, J.3
-
20
-
-
34447632643
-
Angiogenesis in brain tumours
-
Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610-622.
-
(2007)
Nat Rev Neurosci
, vol.8
, pp. 610-622
-
-
Jain, R.K.1
Di Tomaso, E.2
Duda, D.G.3
Loeffler, J.S.4
Sorensen, A.G.5
Batchelor, T.T.6
-
21
-
-
0035253739
-
Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer
-
Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human antivascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-850.
-
(2001)
J Clin Oncol
, vol.19
, pp. 843-850
-
-
Gordon, M.S.1
Margolin, K.2
Talpaz, M.3
-
22
-
-
0035253586
-
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
-
Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19: 851-856.
-
(2001)
J Clin Oncol
, vol.19
, pp. 851-856
-
-
Margolin, K.1
Gordon, M.S.2
Holmgren, E.3
-
23
-
-
49749124673
-
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
-
Lu J-F, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacology. 2008;62:779-786.
-
(2008)
Cancer Chemother Pharmacology
, vol.62
, pp. 779-786
-
-
Lu, J.-F.1
Bruno, R.2
Eppler, S.3
Novotny, W.4
Lum, B.5
Gaudreault, J.6
-
24
-
-
22944452422
-
Pharmacokinetics of therapeutic monoclonal antibodies used in oncology
-
Leveque D, Wisniewski S, Jehl F. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res. 2005;25:2327-2343.
-
(2005)
Anticancer Res
, vol.25
, pp. 2327-2343
-
-
Leveque, D.1
Wisniewski, S.2
Jehl, F.3
-
25
-
-
0032962265
-
Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor
-
Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288:371-378.
-
(1999)
J Pharmacol Exp Ther
, vol.288
, pp. 371-378
-
-
Lin, Y.S.1
Nguyen, C.2
Mendoza, J.L.3
-
26
-
-
33846805155
-
Clinical pharmacokinetics of bevacizumab (Avastin®) following every 2-or 3-week dosing
-
Gaudreault J, Bruno R, Kabbinavar F, Sing A, Johnson DH and Lu J: Clinical pharmacokinetics of bevacizumab (Avastin®) following every 2-or 3-week dosing. J Clin Oncol. 2004;23:205.
-
(2004)
J Clin Oncol
, vol.23
, pp. 205
-
-
Gaudreault, J.1
Bruno, R.2
Kabbinavar, F.3
Sing, A.4
Johnson, D.H.5
Lu, J.6
-
27
-
-
32944482137
-
Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma
-
Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol. 2005;7:369.
-
(2005)
Neuro Oncol
, vol.7
, pp. 369
-
-
Stark-Vance, V.1
-
28
-
-
41649112610
-
Bevacizumab for recurrent malignant glioma: Efficacy, toxicity and patterns of recurrence
-
Norden AD, Youn AS, Setayesh K, et al. Bevacizumab for recurrent malignant glioma: efficacy, toxicity and patterns of recurrence. Neurology. 2008;70:779-787.
-
(2008)
Neurology
, vol.70
, pp. 779-787
-
-
Norden, A.D.1
Youn, A.S.2
Setayesh, K.3
-
29
-
-
33947191055
-
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
-
Vredenburgh JJ, Desjardins A, Herndon JE, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-9.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1253-1259
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon, J.E.3
-
30
-
-
36049037819
-
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
-
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25: 4722-4729.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4722-4729
-
-
Vredenburgh, J.J.1
Desjardins, A.2
Herndon II, J.E.3
-
31
-
-
77951625266
-
Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group
-
Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963-1972.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1963-1972
-
-
Wen, P.Y.1
Macdonald, D.R.2
Reardon, D.A.3
-
32
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733-4740.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
-
33
-
-
77956666382
-
Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study
-
Cloughesy T, Vredenburgh J, Day B, Das A, Friedman HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J Clin Oncol. 2010;28(15):1.
-
(2010)
J Clin Oncol
, vol.28
, Issue.15
, pp. 1
-
-
Cloughesy, T.1
Vredenburgh, J.2
Day, B.3
Das, A.4
Friedman, H.S.5
-
34
-
-
59949083263
-
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
-
Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740-745.
-
(2009)
J Clin Oncol
, vol.27
, pp. 740-745
-
-
Kreisl, T.N.1
Kim, L.2
Moore, K.3
-
35
-
-
75449088610
-
FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme
-
Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14:1131-1138.
-
(2009)
Oncologist
, vol.14
, pp. 1131-1138
-
-
Cohen, M.H.1
Shen, Y.L.2
Keegan, P.3
Pazdur, R.4
-
36
-
-
84861819038
-
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
-
Gil MJ, de las Peñas R, Reynes G, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs. 2012;23:659-665.
-
(2012)
Anti-Cancer Drugs
, vol.23
, pp. 659-665
-
-
Gil, M.J.1
de las Peñas, R.2
Reynes, G.3
-
37
-
-
58149456505
-
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
-
Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neuro Oncol. 2009;91:329-336.
-
(2009)
J Neuro Oncol
, vol.91
, pp. 329-336
-
-
Zuniga, R.M.1
Torcuator, R.2
Jain, R.3
-
38
-
-
58149090856
-
Bevacizumab plus irinotecan in the treatment of patients with progressive recurrent malignant brain tumours
-
Poulsen HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment of patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009;48:52-58.
-
(2009)
Acta Oncol
, vol.48
, pp. 52-58
-
-
Poulsen, H.S.1
Grunnet, K.2
Sorensen, M.3
-
39
-
-
65249185501
-
Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience
-
Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology. 2009;72:1217-1222.
-
(2009)
Neurology
, vol.72
, pp. 1217-1222
-
-
Nghiemphu, P.L.1
Liu, W.2
Lee, Y.3
Than, T.4
Graham, C.5
Lai, A.6
-
40
-
-
78650990754
-
Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study
-
Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010;15:1329-1334.
-
(2010)
Oncologist
, vol.15
, pp. 1329-1334
-
-
Vredenburgh, J.J.1
Cloughesy, T.2
Samant, M.3
-
41
-
-
77954578108
-
Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study
-
Gururangan S, Chi SN, Young Poussaint T, et al. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: A Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28:3069-3075.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3069-3075
-
-
Gururangan, S.1
Chi, S.N.2
Young, P.T.3
-
42
-
-
78650102866
-
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
-
Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12:1300-1310.
-
(2010)
Neuro Oncol
, vol.12
, pp. 1300-1310
-
-
Sathornsumetee, S.1
Desjardins, A.2
Vredenburgh, J.J.3
-
43
-
-
71649094684
-
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study
-
Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;15:101(12):1986-1994.
-
(2009)
Br J Cancer
, vol.101
, Issue.12
, pp. 1986-1994
-
-
Reardon, D.A.1
Desjardins, A.2
Vredenburgh, J.J.3
-
44
-
-
77955242817
-
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma
-
Verhoeff JJ, Lavini C, van Linde ME, et al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010; 21(8):1723-1727.
-
(2010)
Ann Oncol
, vol.21
, Issue.8
, pp. 1723-1727
-
-
Verhoeff, J.J.1
Lavini, C.2
van Linde, M.E.3
-
45
-
-
80053142607
-
Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology)
-
Soffietti R, Trevisan E, Ruda R, et al. Phase II trial of bevacizumab with fotemustine in recurrent glioblastoma: Final results of a multicenter study of AINO (Italian Association of Neuro-oncology). J Clin Oncol. 2011;29(Suppl 15):2027.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 15
, pp. 2027
-
-
Soffietti, R.1
Trevisan, E.2
Ruda, R.3
-
46
-
-
77954748580
-
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progession after radiation therapy and temozololimide: A phase II trial
-
Hasselbach B, Lasseen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progession after radiation therapy and temozololimide: a phase II trial. Neuro Oncol. 2010;12:508-516.
-
(2010)
Neuro Oncol
, vol.12
, pp. 508-516
-
-
Hasselbach, B.1
Lasseen, U.2
Hansen, S.3
-
47
-
-
84861312289
-
Phase 2 study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
-
Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neuro Oncol. 2012;107:155-164.
-
(2012)
J Neuro Oncol
, vol.107
, pp. 155-164
-
-
Reardon, D.A.1
Desjardins, A.2
Peters, K.B.3
-
48
-
-
79952698481
-
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system
-
Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79:1487-1495.
-
(2011)
Int J Radiat Oncol Biol Phys
, vol.79
, pp. 1487-1495
-
-
Levin, V.A.1
Bidaut, L.2
Hou, P.3
-
49
-
-
1342329716
-
Autocrine pathways of the vascular endothelial grow factor (VGEF) in glioblastoma multiforme: Clinical relevance of radiation-induced increase of VGEF levels
-
Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial grow factor (VGEF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VGEF levels. J Neuro Oncol. 2004;66:129-1238.
-
(2004)
J Neuro Oncol
, vol.66
, pp. 129-1238
-
-
Steiner, H.H.1
Karcher, S.2
Mueller, M.M.3
Nalbantis, E.4
Kunze, S.5
Herold-Mende, C.6
-
50
-
-
68649114787
-
Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas
-
Gutin PH, Iwamoto FM, Beal K. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156-163.
-
(2009)
Int J Radiat Oncol Biol Phys
, vol.75
, Issue.1
, pp. 156-163
-
-
Gutin, P.H.1
Iwamoto, F.M.2
Beal, K.3
-
51
-
-
79951984402
-
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
-
Lai A, Nghiemphu PL, Pope WB, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29:142-148.
-
(2011)
J Clin Oncol
, vol.29
, pp. 142-148
-
-
Lai, A.1
Nghiemphu, P.L.2
Pope, W.B.3
-
52
-
-
83955165997
-
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme
-
Vrendenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;82:58-66.
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.82
, pp. 58-66
-
-
Vrendenburgh, J.J.1
Desjardins, A.2
Kirkpatrick, J.P.3
-
53
-
-
79958210803
-
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed gliobastoma multiforme
-
Chinot O, de la Motte Rouge T, Moore N, et al. AVAglio: phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed gliobastoma multiforme. Adv Ther. 2011;28:334-340.
-
(2011)
Adv Ther
, vol.28
, pp. 334-340
-
-
Chinot, O.1
de la Motte, R.T.2
Moore, N.3
-
54
-
-
84876306495
-
Phase III Trial of Bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Final progression-free survival and interim overall survival results in Avaglio
-
doi:10.1093/neuonc/nos232
-
Chinot O, Wick W, Mason W, Henriksson R, Sarn F, Nishikawa R, et al. Phase III Trial of Bevacizumab added to standard radiotherapy and temozolomide for newly-diagnosed glioblastoma: Final progression-free survival and interim overall survival results in Avaglio. Neuro-Oncology. 2012;14 (suppl 6): vi101-vi105. doi:10.1093/neuonc/nos232).
-
(2012)
Neuro-Oncology
, vol.14
, Issue.SUPPL. 6
-
-
Chinot, O.1
Wick, W.2
Mason, W.3
Henriksson, R.4
Sarn, F.5
Nishikawa, R.6
-
55
-
-
84866759977
-
Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma
-
Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012;42:887-895.
-
(2012)
Jpn J Clin Oncol
, vol.42
, pp. 887-895
-
-
Nagane, M.1
Nishikawa, R.2
Narita, Y.3
-
56
-
-
36849019200
-
Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
-
Raval S, Hwang S, Dorsett L. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2007; 25(suppl 18):2078.
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL. 18
, pp. 2078
-
-
Raval, S.1
Hwang, S.2
Dorsett, L.3
-
57
-
-
52949097474
-
Safety of anticoagulation use and bevacizumab in patients with glioma
-
Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008;10:355-360.
-
(2008)
Neuro Oncol
, vol.10
, pp. 355-360
-
-
Nghiemphu, P.L.1
Green, R.M.2
Pope, W.B.3
Lai, A.4
Cloughesy, T.F.5
-
58
-
-
36849019200
-
Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM)
-
Raval S, Hwang S, Dorsett L. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2007;25(Suppl).
-
(2007)
J Clin Oncol
, vol.25
, Issue.SUPPL.
-
-
Raval, S.1
Hwang, S.2
Dorsett, L.3
-
59
-
-
46149123043
-
Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study
-
Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris). 2008;164:588-594.
-
(2008)
Rev Neurol (Paris)
, vol.164
, pp. 588-594
-
-
Guiu, S.1
Taillibert, S.2
Chinot, O.3
-
60
-
-
58149231546
-
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas
-
Desjardins A, Reardon DA, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008;14: 7068-7073.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7068-7073
-
-
Desjardins, A.1
Reardon, D.A.2
Herndon, J.E.3
-
61
-
-
0032784243
-
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers
-
Young AH, Sahakian BJ, Robbins TW, Cowen PJ. The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl). 1999;145:260-266.
-
(1999)
Psychopharmacology (Berl)
, vol.145
, pp. 260-266
-
-
Young, A.H.1
Sahakian, B.J.2
Robbins, T.W.3
Cowen, P.J.4
-
62
-
-
49349111000
-
The use and toxicity of steroids in the management of patients with brain metastases
-
Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer. 2008;16:1041-1048.
-
(2008)
Support Care Cancer
, vol.16
, pp. 1041-1048
-
-
Sturdza, A.1
Millar, B.A.2
Bana, N.3
-
63
-
-
79959947030
-
Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab
-
Wefel JS, Cloughesy T, Zazzali JL, et al. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2001;13:660-668.
-
(2001)
Neuro Oncol
, vol.13
, pp. 660-668
-
-
Wefel, J.S.1
Cloughesy, T.2
Zazzali, J.L.3
-
64
-
-
80053145837
-
Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials
-
Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Coan AD, Hemdon JE, et al. Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J Clin Oncol. 2011;29 (suppl 19):2030.
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 19
, pp. 2030
-
-
Reardon, D.A.1
Vredenburgh, J.J.2
Desjardins, A.3
Peters, K.4
Coan, A.D.5
Hemdon, J.E.6
-
65
-
-
79951486845
-
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
-
Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology. 2011;76: 432-437.
-
(2011)
Neurology
, vol.76
, pp. 432-437
-
-
Pope, W.B.1
Xia, Q.2
Paton, V.E.3
-
66
-
-
84878966084
-
Do we know the optimal bevacizumab dose in recurrent malignant glioma (MG)? The experience of the Spanish Group GEINO with bevacizumab 5 mg/kg
-
doi:10.1093/neuonc/nos232
-
Gil-Gil MJ, Fuster J, Balaña C, Benavides M, Mesia C, Etxaniz O, et al. Do we know the optimal bevacizumab dose in recurrent malignant glioma (MG)? The experience of the Spanish Group GEINO with bevacizumab 5 mg/kg. Neuro-Oncology. 2012; 14 (suppl 6): vi101-vi105.doi:10.1093/neuonc/nos232.
-
(2012)
Neuro-Oncology
, vol.14
, Issue.SUPPL. 6
-
-
Gil-Gil, M.J.1
Fuster, J.2
Balaña, C.3
Benavides, M.4
Mesia, C.5
Etxaniz, O.6
|